Posts by: Iqra Mumal

Lung Cancer, News

E-cigarettes carry much less cancer risk than tobacco smoke, although some types are more risky than others, a study shows. The research, “Comparing the cancer potencies of emissions from vapourised ... Read more

August 23, 2017August 23, 2017

AdAlta Presenting Data on Therapy Candidate AD-114 at Inaugural IPF Summit

Idiopathic Pulmonary Fibrosis, News

AdAlta‘s investigative therapy AD-114, developed for the treatment of idiopathic pulmonary fibrosis (IPF), are in the spotlight at the inaugural IPF Summit Aug. 21-23 in Boston. The IPF Summit brings together leading researchers and pharmaceutical ... Read more

August 15, 2017August 15, 2017

Genentech’s Alecensa Granted Priority Review for First-line Treatment of ALK-positive Advanced NSCLC

News

The U.S. Food and Drug Administration (FDA) granted priority review to Genentech’s Alecensa (alectinib) as a first-line treatment for ALK-positive, locally advanced or metastatic NSCLC (non-small cell lung cancer). It also accepted ... Read more

July 28, 2017July 28, 2017

Ofev Improves Microvascular Architecture in Mouse Model of Lung Fibrosis

Idiopathic Pulmonary Fibrosis, News

Ofev (nintedanib) improved microvascular architecture in a mouse model of lung fibrosis, uncovering a potential new mode of action through which the therapy works to treat idiopathic pulmonary fibrosis (IPF). The study ... Read more

June 6, 2017June 6, 2017

Mechanical Ventilation Most Often Given Younger IPF Patients and Raises Risk of Death, Study Finds

Idiopathic Pulmonary Fibrosis, News

Mechanical ventilation given idiopathic pulmonary fibrosis (IPF) patients in respiratory distress is associated with a four-fold increase in hospital costs and a seven-fold increase in in-hospital mortality, a new study finds. ... Read more

May 24, 2017June 19, 2017

INOpulse Nitric Oxide System Seen to Treat PH Patients with IPF and COPD Symptoms

COPD, Idiopathic Pulmonary Fibrosis, News, Pulmonary Hypertension

The INOpulse nitric oxide delivery system met its primary Phase 2 clinical trial goal of increasing the blood-vessel volume of pulmonary hypertension patients with idiopathic pulmonary fibrosis (PH-IPF), according to its maker, Bellerophon Therapeutics. ... Read more